Analysis for Life

Manufactures handheld mass spectroscopy instruments for chemical and biomolecular analysis for the field forensics and bioprocessing sectors.

Sector

Life sciences tools

Partner since

April 2019
908 Devices logo and an instrument

Sands Capital first partnered with 908 Devices through its Series E round in April 2019. We assisted the company in securing investors for this round. Our team has continued to counsel management on forming strategic relationships and navigating the IPO process.

The case studies provided herein are a selection of investments that we believe illustrate our investment approach and philosophy, as well as the range of businesses in which Sands Capital typically invests. They were selected on an objective basis. The case studies are being provided for discussion purposes only and the information included should not be relied upon to make any investment decision. The full portfolio holdings are available here.

Related Insights

06.02.2022
Machine Learning Can Strengthen Defense Against Cyber Threats
a man standing in the room with monitors
05.05.2022
Life Sciences Revolution Unlocks Potential in Tools, Diagnostics, and Therapeutics
doctors examining the brain x-ray
10.24.2021
As Physical and Virtual Worlds Converge, Digital Markets Emerge
man walking over the city wearing VR glasses
09.30.2021
Sands Capital Names Ian Ratcliffe to Executive Management Team
Member man in suit smiling pictures in frames on the wall
07.20.2021
Identity Intelligence is Critical to Cybersecurity in Ever-more Digital World
bright spots in the brain